Relevant bibliographies by topics / Atopic dermatitis Treatment Malaysia

Academic literature on the topic 'Atopic dermatitis Treatment Malaysia'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Atopic dermatitis Treatment Malaysia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Atopic dermatitis Treatment Malaysia"

1

Kim, Hei Sung, and Sang Hyun Cho. "Treatment for atopic dermatitis." Journal of the Korean Medical Association 57, no. 3 (2014): 226. http://dx.doi.org/10.5124/jkma.2014.57.3.226.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ha, Seog Jun, and Jin Wou Kim. "Treatment of Atopic Dermatitis." Journal of the Korean Medical Association 43, no. 10 (2000): 1013. http://dx.doi.org/10.5124/jkma.2000.43.10.1013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Krafchik, Bernice R. "Treatment of Atopic Dermatitis." Journal of Cutaneous Medicine and Surgery 3, no. 2_suppl (February 1999): S2–16—S2–23. http://dx.doi.org/10.1177/12034754990030s204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wergowske, Gilbert L. "Treatment-Resistant Atopic Dermatitis." Journal of the American Geriatrics Society 49, no. 7 (July 2001): 1008–9. http://dx.doi.org/10.1046/j.1532-5415.2001.49200.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Engler, D., F. Makola, and N. M. Magongwa. "Atopic Dermatitis." South African Family Practice 60, no. 6 (November 30, 2018): 26–33. http://dx.doi.org/10.4102/safp.v60i6.4932.

Full text
Abstract:
The aetiology of atopic dermatitis is multi-faceted and affects our first line host defence, the skin. Atopic dermatitis has a significant influence on a patient’s social and occupational functioning and can have long-lasting effects. The signs and symptoms of AD includes pruritus, erythema, fissuring, and lichenification – these are reduced by the use of moisturizing agents. Guidelines on how to manage atopic dermatitis aims to improve symptoms and achieve long-term disease control. Patient education remains as important as other treatment strategies and the pharmacist plays an integral role in educating patients on the management of their condition and adherence to therapy.
APA, Harvard, Vancouver, ISO, and other styles
6

Bata-Csörgő, Zsuzsanna. "Systemic treatment of atopic dermatitis." Bőrgyógyászati és Venerológiai Szemle 93, no. 5 (October 20, 2017): 240–42. http://dx.doi.org/10.7188/bvsz.2017.93.5.8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thestrup-Pedersen, K. "Treatment principles of atopic dermatitis." Journal of the European Academy of Dermatology and Venereology 16, no. 1 (January 2002): 1–9. http://dx.doi.org/10.1046/j.1468-3083.2002.00349.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hsu, Chih-Jung, and Li-Fang Wang. "Emerging Treatment of Atopic Dermatitis." Clinical Reviews in Allergy & Immunology 33, no. 3 (July 13, 2007): 199–203. http://dx.doi.org/10.1007/s12016-007-0043-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Boguniewicz, Mark. "Topical treatment of atopic dermatitis." Immunology and Allergy Clinics of North America 24, no. 4 (November 2004): 631–44. http://dx.doi.org/10.1016/j.iac.2004.06.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Esteve-Martínez, A., A. García-Rabasco, J. Miralles, and J. de-la-Cuadra-Oyanguren. "Treatment-Resistant Adult Atopic Dermatitis." Actas Dermo-Sifiliográficas (English Edition) 102, no. 10 (December 2011): 821–22. http://dx.doi.org/10.1016/j.adengl.2012.01.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Atopic dermatitis Treatment Malaysia"

1

Devillers, A. C. A. "Diagnostic work-up and treatment of severe and/or refractory atopic dermatitis." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2009. http://hdl.handle.net/1765/14802.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schmitt, Jochen, Michael Meurer, Uta Schwanebeck, Xina Grählert, and Knut Schäkel. "Treatment Following an Evidence-Based Algorithm versus Individualised Symptom-Oriented Treatment for Atopic Eczema." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-135477.

Full text
Abstract:
Background: Evidence-based treatment algorithms, successfully established for asthma, are missing for atopic eczema (AE). Objectives: To investigate whether treatment according to an evidence-based algorithm is an effective and applicable concept for the management of AE. Methods: Based on a systematic literature review, we developed an evidence-based severity-score-oriented treatment algorithm for AE and compared its effectiveness to that of an individualised symptom-oriented treatment (individual therapy) in a randomised controlled trial. Sixty-three participants were randomised to algorithm (n = 32) or individual therapy (n = 31) and treated accordingly for 12 months. Study end points included difference between baseline SCORAD and mean SCORAD under treatment (primary end point), quality of life and treatment utilisation. Analysis was by intention to treat (registration: ClinicalTrials.gov:NCT00148746). Results: No statistically significant differences in clinical or subjective response were observed between groups. Treatment following the algorithm and individual treatment both effectively controlled AE. Mean SCORAD reductions were 47% (95% confidence interval, CI = 38–55; algorithm) and 42% (95% CI = 29–54; individual). Clinical response was paralleled by improved quality of life in both groups. Physicians adhered to the algorithm option in 93% of their treatment decisions. Conclusion: Treatment following an evidence-based algorithm is an effective and applicable concept for the management of AE but does not show clear advantages compared to individualised treatment in a dermatological setting
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
3

Dalton, Sarah J. "Controlled studies of emollient ointments and creams in the treatment of atopic dermatitis in childhood." Thesis, University of Manchester, 1999. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.545915.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chang, Chen J. B. "A hexa-herbal Chinese formula for treatment of atopic dermatitis : phytochemical analysis and selected anti-inflammatory activities." Thesis, University College London (University of London), 2017. http://discovery.ucl.ac.uk/1560129/.

Full text
Abstract:
Diverse pharmacological activities and the solid clinical performance of Chinese herbal medicines have attracted worldwide attention in terms of its modernization. Here, a hexaherbal Chinese formula (HHCF) for treating atopic dermatitis (AD) topically has been studied from chemical and biological perspectives. The HHCF comprises the rootstock of Scutellaria baicalensis Georgi (SCU), Rheum tanguticum Maxim. Ex Balf. (RHE), Sophora flavescens Aiton (SOP); the root bark of Dictamnus dasycarpus Turcz. (DIC); the bark of Phellodendron chinense C.K. Schneid. (PHE) and the fruit of Kochia scoparia (L.) Schrad. (KOC). In this thesis the chemical composition of the HHCF has been profiled and characterized using liquid-chromatography (LC) coupled with triple quadruple mass spectrometry (MS). 68 chemical compounds including alkaloids, anthraquinones, coumarins, flavonoids, naphthalene derivatives, phenylbutanone glucosides, phenolic acids, pterocarpans, stilbenes and tannins were putatively identified in the LC-MS profile of the HHCF based on mass measurement and characteristic fragment ions. The source(s) of these chemical compounds has been analyzed using the developed EXCEL template and PHE, RHE and SOP contributed the largest number of chemical compounds identified in the HHCF, while KOC seems to contribute very little. To evaluate the anti-inflammatory effects of the HHCF for treating AD/skin inflammation, the thymus and activation-regulated chemokine (CCL17), Prostaglandin E2 (PGE2), IL-8, IL-6 and hyaluronidase inhibitory effects were studies in vitro. Results showed that the HHCF inhibited hyaluronidase activity, TNF-α- plus IFN--induced CCL17 production in spontaneously immortalized human epidermal keratinocytes (HaCaT) and IL-1β-induced PGE2 in human fibroblasts with no effects on IL-8 and IL- 6. Among the chemical compounds characterized in LC-MS profile of the HHCF, multivariate regression models indicated the major contributor to the CCL17 inhibition were berberine, catechin dimers, gallic acid, galloylglucose, 4-(4'-hydroxylphenyl)-2- butanone 4'-O-β-D-glucoside, pyrogallol and resveratrol 4'-O-β-D-(6''-O-galloyl) glucoside. The effects of the HHCF against other pathogenesis-related targets need to be further study to ascertain its therapeutic efficacy against AD.
APA, Harvard, Vancouver, ISO, and other styles
5

Schmitt, Jochen, Michael Meurer, Uta Schwanebeck, Xina Grählert, and Knut Schäkel. "Treatment Following an Evidence-Based Algorithm versus Individualised Symptom-Oriented Treatment for Atopic Eczema: A Randomised Controlled Trial." Karger, 2008. https://tud.qucosa.de/id/qucosa%3A27651.

Full text
Abstract:
Background: Evidence-based treatment algorithms, successfully established for asthma, are missing for atopic eczema (AE). Objectives: To investigate whether treatment according to an evidence-based algorithm is an effective and applicable concept for the management of AE. Methods: Based on a systematic literature review, we developed an evidence-based severity-score-oriented treatment algorithm for AE and compared its effectiveness to that of an individualised symptom-oriented treatment (individual therapy) in a randomised controlled trial. Sixty-three participants were randomised to algorithm (n = 32) or individual therapy (n = 31) and treated accordingly for 12 months. Study end points included difference between baseline SCORAD and mean SCORAD under treatment (primary end point), quality of life and treatment utilisation. Analysis was by intention to treat (registration: ClinicalTrials.gov:NCT00148746). Results: No statistically significant differences in clinical or subjective response were observed between groups. Treatment following the algorithm and individual treatment both effectively controlled AE. Mean SCORAD reductions were 47% (95% confidence interval, CI = 38–55; algorithm) and 42% (95% CI = 29–54; individual). Clinical response was paralleled by improved quality of life in both groups. Physicians adhered to the algorithm option in 93% of their treatment decisions. Conclusion: Treatment following an evidence-based algorithm is an effective and applicable concept for the management of AE but does not show clear advantages compared to individualised treatment in a dermatological setting.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
6

Zook, Tiffany Anne Crawford, and Tiffany Anne Crawford Zook. "Development and Evaluation of a Clinical Practice Guideline to Promote Evidence-Based Treatment of Childhood Atopic Dermatitis in Primary Care." Diss., The University of Arizona, 2016. http://hdl.handle.net/10150/621743.

Full text
Abstract:
ABSTRACT Introduction and Rationale: Atopic Dermatitis (AD) is a common skin condition, characterized by markedly pruritic eczematous lesions, that most often presents in childhood. The majority of children diagnosed with AD will have mild disease and will first present with symptoms to a primary care provider (PCP), however approximately 85% of pediatricians only provide limited initial care followed by a referral to dermatology (Eichenfield et al., 2015). While there are specialty care based treatment guidelines for childhood AD, there are no guidelines available that specifically address primary care management of childhood AD. Purpose and Objective: The primary purpose of this DNP project is to develop an evidence-based clinical practice guideline (CPG) for pediatric PCPs. The secondary purpose is to develop a corresponding atopic dermatitis action plan (ADAP) to be used by children and parents. The objective is to equip PCPs to better manage children with AD in the primary care setting and to guide patients and parents in the importance of daily control measures and in the individualized treatment plan prescribed by the PCP. Methods: The Appraisal of Guidelines for Research & Evaluation II (AGREE II) framework and Social Cognitive Theory (SCT) serve as the theoretical frameworks for CPG and ADAP development. The American Academy of Pediatrics (AAP) process for evidence based policy setting is used as a model for key action statement development. Results: Evaluation of the CPG was completed using the AGREE II tool, a reliable and validated tool for evaluating CPGs. Five of the six domains evaluated, yielded combined scores of at least 90%, with one domain a combined score of 63%. The overall standard deviation was 0.58, indicating an overall low level of user discrepancy Additions and revisions were made based on the results of the AGREE II evaluation scores with specific emphasis on the lowest scoring domain. Conclusion: This DNP Project identified the need for a CPG specific to pediatric primary care. A CPG with accompanying ADAP was developed and evaluated using the AGREE II tool. The CPG was found to meet the recommended standards and recommended for use in pediatric primary care.
APA, Harvard, Vancouver, ISO, and other styles
7

Finberg, Marike Johanna. "A comparative study for the topical treatment of atopic dermatitis with Aloe ferox and Aloe vera in Balb/c mice." Diss., University of Pretoria, 2013. http://hdl.handle.net/2263/40699.

Full text
Abstract:
Atopic dermatitis (AD) typically develops in patients with a history of allergic ailments, and is characterised by an itchy, inflammatory skin condition with scaling, lichenification, papules, excoriations and pruritus. In AD patients a chronic relapsing inflammatory condition is seen, associated with IgE hyper production. AD flares are largely triggered by environmental factors. However, the exact etiology of AD is unclear and there is a pressing need for new treatment regimens as AD is a chronic condition and requires long term treatment. Historically Aloe has been used to treat skin conditions as well as a variety of other diseases. To further explore the pathogenesis and treatment of AD, Balb/c mice were sensitized and challenged with 2,4-dinitrochlorobenzene (DNCB) for atopic dermatitis induction. Thereafter, mice were treated with either Aloe ferox or Aloe vera applied daily on the dorsal skin for 10 consecutive days. A placebo gel was used for the control mice. Blood was collected at the end of the treatment period and serum IgE levels measured. Serum IgE levels were significantly lowered in the Aloe ferox group than in the Aloe vera group. This study demonstrated Aloe’s immunoregulatory potential for alleviating atopic dermatitis through influencing of Th2 cell activation.
Dissertation (MSc)--University of Pretoria, 2013.
gm2014
Pharmacology
unrestricted
APA, Harvard, Vancouver, ISO, and other styles
8

Schmitt, Jochen, Elisabeth Heese, Gottfried Wozel, and Michael Meurer. "Effectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity in Atopic Dermatitis and Psoriasis Vulgaris – A Prospective Study." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-135494.

Full text
Abstract:
Background: Financial constraints challenge evidence of the effectiveness of dermatological inpatient management. Objective: To evaluate the effectiveness of hospitalization in atopic dermatitis and psoriasis regarding initial and sustained benefits. Methods: Prospective study on adults with psoriasis vulgaris (n = 22) and atopic dermatitis (n = 14). At admission, discharge, and 3 months after discharge, validated outcomes of objective and subjective disease severity were assessed by trained investigators. Results: Hospitalization resulted in substantial benefit in quality of life and clinical disease severity. Looking at mean scores, the observed benefit appeared stable until 3-month follow-up. The analysis of individual patient data revealed significant changes in disease severity between discharge and 3-month follow-up with some patients relapsing, others further improving. Reasons for hospitalization and treatment performed were not related to sustained benefit. Conclusions: In psoriasis vulgaris and atopic dermatitis, hospitalization effectively improved quality of life and clinical disease severity. Further research should focus on prognostic factors for sustained improvement
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
9

Schmitt, Jochen, Elisabeth Heese, Gottfried Wozel, and Michael Meurer. "Effectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity in Atopic Dermatitis and Psoriasis Vulgaris – A Prospective Study." Karger, 2007. https://tud.qucosa.de/id/qucosa%3A27655.

Full text
Abstract:
Background: Financial constraints challenge evidence of the effectiveness of dermatological inpatient management. Objective: To evaluate the effectiveness of hospitalization in atopic dermatitis and psoriasis regarding initial and sustained benefits. Methods: Prospective study on adults with psoriasis vulgaris (n = 22) and atopic dermatitis (n = 14). At admission, discharge, and 3 months after discharge, validated outcomes of objective and subjective disease severity were assessed by trained investigators. Results: Hospitalization resulted in substantial benefit in quality of life and clinical disease severity. Looking at mean scores, the observed benefit appeared stable until 3-month follow-up. The analysis of individual patient data revealed significant changes in disease severity between discharge and 3-month follow-up with some patients relapsing, others further improving. Reasons for hospitalization and treatment performed were not related to sustained benefit. Conclusions: In psoriasis vulgaris and atopic dermatitis, hospitalization effectively improved quality of life and clinical disease severity. Further research should focus on prognostic factors for sustained improvement.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
10

Sturesdotter, Hoppe Torborg. "Skin Barrier Function and mRNA Expression Profiles in Patients with Atopic Dermatitis, Ichthyosis Vulgaris, and X-linked Recessive Ichthyosis : Aetiopathogenic Differences and the Impact of Moisturizing Treatment." Doctoral thesis, Uppsala universitet, Dermatologi och venereologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-192396.

Full text
Abstract:
Atopic dermatitis (AD), ichthyosis vulgaris (IV), and X-linked recessive ichthyosis (XLRI) are characterized by dry skin and impaired skin barrier. AD and IV are related to loss-of-function mutations in FLG (encoding filaggrin), whereas XLRI is caused by deletions or inactivating mutations in the steroid sulphatase gene (STS). Patients regularly use moisturizing creams, but little is known about the creams’ effects on the skin barrier. The present work combines objective scorings, non-invasive techniques, and molecular analyses of skin biopsies to characterize the skin in 57 patients with AD, IV, or XLRI, and in 14 healthy controls. Patients were classified according to their FLG and STS mutation status: AD with FLG+/+ (n = 14), AD with FLG+/– (n = 14), AD/IV with FLG–/– (n = 15), and XLRI with STS– (n = 14), as well as one man with a novel point mutation. Assessments were conducted at baseline and after four weeks of treatment with three different moisturizers applied to volar forearm skin. At baseline, dryness scoring and non-invasive assessments verified impaired skin barrier function in all patients. In patients with AD/IV, microarray analysis identified 300–3000 up- or downregulated mRNA transcripts involved in signalling pathways important for inflammation and barrier repair. The skin phenotype and number of altered transcripts were correlated with the FLG mutation status, with FLG–/– patients displaying the highest transepidermal water loss (TEWL) and the most altered transcript levels. In contrast, despite an equally dysfunctional skin barrier, only limited changes in mRNA transcripts occurred in XLRI patients. Treatment with moisturizers improved skin dryness similarly in all groups, but TEWL behaved differently: it decreased slightly in the AD/IV group and increased in the XLRI group, especially after urea treatment. Only minute effects on skin pH and mRNA expression were observed. In conclusion, FLG mutations elicit pro-inflammatory mechanisms probably aimed at restoring barrier competence. This does not occur in patients with XLRI, presumably because STS deficiency automatically increases the barrier thickness. Moisturizing treatment improves skin dryness in patients with AD, IV, or XLRI, but does not seem to normalize the altered epidermal gene expression profile in AD/IV patients.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Atopic dermatitis Treatment Malaysia"

1

Bridgett, Christopher. Atopic skin disease: A manual for practitioners. Petersfield, U.K: Wrightson Biomedical, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Takafumi, Etō, and Nihon Arerugī Tomo no Kai, eds. Yi wei xing pi fu yan: Huan zhe zui xiang zhi dao de 101 ge da an. Taibei Shi: Taiwan dong fan gu fen you xian gong si, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kiyomasu, Takahiro. Sasa to wakaru "atopī o tadashiku shitte naosu shinjōshiki". Tōkyō: Kōdansha, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Allergies sourcebook: Basic consumer health information about the immune system and allergic disorders, including rhinitis (hay fever), sinusitis, conjunctivitis, asthma, atopic dermatitis, and anaphylaxis, and allergy triggers such as pollen, mold, dust mites, animal dander, chemicals, foods and additives, and medications; along with facts about allergy diagnosis and treatment, tips on avoiding triggers and preventing symptoms, a glossary of related terms, and directories of resources for additional help. Detroit, MI: Omnigraphics, Inc., 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Allergies sourcebook: Basic consumer health information about the immune system and allergic disorders, including rhinitis (hay fever), sinusitis, conjunctivitis, asthma, atopic dermatitis, and anaphylaxis, and allergy triggers such as pollen, mold, dust mites, animal dander, chemicals, foods and additives, and medications ; along with facts about allergy diagnosis and treatment, tips on avoiding triggers and preventing symptoms, a glossary of related terms, and directories of resources for additional help and information. 4th ed. Detroit: Omnigraphics, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Leung, Donald Y. M., 1949-, ed. Atopic dermatitis: From pathogensis to treatment. New York: Springer-Verlag, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Leung, Donald Y. M. Atopic Dermatitis: From Pathogensis to Treatment (Medical Intelligence Unit). R G Landes Co, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Steinhoff, Martin, Thomas A. Luger, and Sakari Reitamo. Textbook of Atopic Dermatitis. Taylor & Francis Group, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Textbook of Atopic Dermatitis. Informa Healthcare, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Steinhoff, Martin, Thomas A. Luger, and Sakari Reitamo. Textbook of Atopic Dermatitis. Taylor & Francis Group, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Atopic dermatitis Treatment Malaysia"

1

Ring, Johannes. "Special Therapeutic Options and Substances in the Treatment of Atopic Eczema." In Atopic Dermatitis, 129–66. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-22243-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rajka, G. "Treatment of Atopic Dermatitis." In Pediatric Dermatology, 114–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71524-2_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kolli, Sree S., Adrian Pona, Abigail Cline, Lindsay C. Strowd, and Steven R. Feldman. "Adherence in Atopic Dermatitis." In Treatment Adherence in Dermatology, 75–84. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-27809-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Allen, Herbert B. "Treatment." In The Etiology of Atopic Dermatitis, 57–68. London: Springer London, 2014. http://dx.doi.org/10.1007/978-1-4471-6545-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hong, Seung-Phil. "Topical Treatment." In Practical Insights into Atopic Dermatitis, 157–75. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8159-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Ji Hyun, and Joo Young Roh. "Treatment Algorithms." In Practical Insights into Atopic Dermatitis, 235–40. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8159-5_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Park, Chang Ook. "Systemic Treatment." In Practical Insights into Atopic Dermatitis, 177–96. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8159-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bos, J. D. "Current Treatment of Atopic Dermatitis." In Tacrolimus Ointment, 63–77. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-662-10209-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Miehe, U., W. Kiess, and F. Prenzel. "Topical Treatment of Atopic Dermatitis." In Pediatric and Adolescent Medicine, 101–12. Basel: KARGER, 2011. http://dx.doi.org/10.1159/000328178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Patel, Nupur, and Lindsay C. Strowd. "The Future of Atopic Dermatitis Treatment." In Advances in Experimental Medicine and Biology, 185–210. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-64804-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Atopic dermatitis Treatment Malaysia"

1

Palomo-Palomo, C., MM Romero Alonso, D. Guerra Estevez, M. Barrera Ledesma, and J. Estaire Gutierrez. "4CPS-025 Dupilumab in the treatment of moderate to severe atopic dermatitis: case reports." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Moothanchery, Mohesh, Amalina Binte Ebrahim Attia, Xiuting Li, Yew Yik Weng, Steven Thng, Dinish U.S., and Malini Olivo. "Assessment of oxygen saturation in microvasculature of atopic dermatitis patients using multispectral optoacoustic mesoscopy." In Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2022, edited by Tianhong Dai, Mei X. Wu, and Jürgen Popp. SPIE, 2022. http://dx.doi.org/10.1117/12.2610600.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Barbato, L., G. Gandini, L. Benda, S. Manfre’, and P. Marini. "4CPS-232 Use of dupilumab in the treatment of atopic dermatitis in real clinical practice." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.64.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Torres, P. Pelegrin, C. de Gorostiza, FJ Bécares, EM Martin, L. García, M. Hernandez, and MA Arias. "4CPS-139 Study assessing the use of high-cost off-label drugs in the treatment of atopic dermatitis." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Piwowarski, JP, M. Sacharczuk, W. Skowrońska, and S. Granica. "Application of urolithin A – a postbiotic metabolite produced by human gut microbiota, in topical treatment of atopic dermatitis." In GA – 70th Annual Meeting 2022. Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1759005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Casas Hidalgo, I., A. Rodríguez Delgado, ÁS Raquel, and A. Madrid Paredes. "4CPS-038 Quality of life of patients with moderate-to-severe atopic dermatitis undergoing out-patient treatment with dupilumab." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rubini, Norma, Jonathan Silverberg, Mario Pires, Ana Rossi, Annie Zhang, Zeng Chen, Noah Levit, Jingdong Chao, Brad Shumel, and Gaëlle Bagousse. "Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from seven randomized, placebo-controlled studies." In International Symposium on Immunobiological. Instituto de Tecnologia em Imunobiológicos, 2021. http://dx.doi.org/10.35259/isi.2021_46560.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Atopic dermatitis Treatment Malaysia"

1

Ghirozi, Isadora Bueloni, Rebeka Bustamante Rocha, Heloi Jose Stefani, Yasmin Luz Lima de Mesquita, Everton Bruno Castanha, and Lais Lopes Almeida Gomes. Efficacy and safety of dupilumab for atopic dermatitis in children and adolescents. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0160.

Full text
Abstract:
Review question / Objective: Is dupilumab effective for treatment of children and adolescentes with moderate to severe atopic dermatitis? Does it improve SCORAD outomes? Does it reduce pruritus? Does it improve quality of life? Does improve sleep quality? Condition being studied: Atopic dermatitis is a common and chronic skin disease characerized by inflammation, pruritus and dryness of the skin. Diminished quality of life, sleeping problems and intense chronic pruritus are among the consequences faced by patients with atopic dermatitis, especially those with moderate to severe presentations of the disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Xiao, Yangjian, Yuan Yan, Zhiyu Hong, and Jie Li. Abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Atopic dermatitis Treatment Malaysia' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography